ArticleOncoimmunology2012
Trial Watch: Adoptive cell transfer immunotherapy.
Article in Oncoimmunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02661685 (An Immunotherapy for Metastatic Cancer Patients by Adoptive Transfer of Autologous IKDC-like Cells - Phase 1 Clinical Trial), which is not on this map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Immunotherapy for Metastatic Cancer Patients by Adoptive Transfer of Autologous IKDC-like Cells - Phase 1 Clinical Trial
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Specific immunotherapy in hepatocellular cancer: A systematic review.Journal of gastroenterology and hepatology · 2017Pooled it
- Phase I/II study of adjuvant immunotherapy with sentinel lymph node T lymphocytes in patients with colorectal cancer.Cancer immunology, immunotherapy : CII · 2015Trial
- Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Review
- Microbial metabolite-driven immune reprogramming in tumor immunotherapy: mechanisms and therapeutic perspectives.Frontiers in immunology · 2025Review
- Digital Pathology for Better Clinical Practice.Cancers · 2024Review
- Principles of risk assessment in colon cancer: immunity is key.Oncoimmunology · 2024Review
- Artificial intelligence for chimeric antigen receptor-based therapies: a comprehensive review of current applications and future perspectives.Therapeutic advances in vaccines and immunotherapy · 2024Review
- Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response.Oncoimmunology · 2023Review
- Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy.Cancer cell international · 2022Review
- A novel multimeric IL15/IL15Rα-Fc complex to enhance cancer immunotherapy.Oncoimmunology · 2021Article
- The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.Nature reviews. Cancer · 2020Review
- Receptor-interacting protein kinase 1 is a key mediator in TLR3 ligand and Smac mimetic-induced cell death and suppresses TLR3 ligand-promoted invasion in cholangiocarcinoma.Cell communication and signaling : CCS · 2020Article
- Chemotherapy combined with dendritic cell vaccine and cytokine-induced killer cells in the treatment of colorectal carcinoma: a meta-analysis.Cancer management and research · 2018Article
- Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer.Bioengineered · 2017Article
- Specific immunotherapy in renal cancer: a systematic review.Therapeutic advances in urology · 2017Review
- A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy.Journal of hematology & oncology · 2017Review
- Trial Watch: Adoptive cell transfer for oncological indications.Oncoimmunology · 2015Review
- Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant State.Vaccines · 2015Review
- Extending the lifespan and efficacies of immune cells used in adoptive transfer for cancer immunotherapies-A review.Oncoimmunology · 2015Review
- The progress of immunotherapy for glioblastoma.Human vaccines & immunotherapeutics · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the last two decades, several approaches for the activation of the immune system against cancer have been developed. These include rather unselective maneuvers such as the systemic administration of immunostimulatory agents (e.g., interleukin-2) as well as targeted interventions, encompassing highly specific monoclonal antibodies, vaccines and cell-based therapies. Among the latter, adoptive cell transfer (ACT) involves the selection of autologous lymphocytes with antitumor activity, their expansion/activation ex vivo, and their reinfusion into the patient, often in the context of lymphodepleting regimens (to minimize endogenous immunosuppression). Such autologous cells can be isolated from tumor-infiltrating lymphocytes or generated by manipulating circulating lymphocytes for the expression of tumor-specific T-cell receptors. In addition, autologous lymphocytes can be genetically engineered to prolong their in vivo persistence, to boost antitumor responses and/or to minimize side effects. ACT has recently been shown to be associated with a consistent rate of durable regressions in melanoma and renal cell carcinoma patients and holds great promises in several other oncological settings. In this Trial Watch, we will briefly review the scientific rationale behind ACT and discuss the progress of recent clinical trials evaluating the safety and effectiveness of adoptive cell transfer as an anticancer therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.